Related Experiment Video
Updated: Apr 20, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
The cardiorenal problem
Emiliy Pollock1, Albina Nowak1
1Division of Internal Medicine, University Hospital Zurich, Zurich, Switzerland.
Insights
Cardiorenal syndrome (CRS) involves harmful interactions between heart and kidney dysfunction, affecting many patients. New serum markers may improve CRS diagnosis, with diuretics and ACE inhibitors as primary treatments.
Area of Science:
- Cardiology
- Nephrology
- Internal Medicine
Background:
- Cardiorenal syndrome (CRS) is a prevalent condition characterized by the detrimental interplay between cardiac and renal dysfunction.
- CRS has a high mortality rate and encompasses five clinical subtypes.
- Common pathogenetic mechanisms include neurohumoral and hemodynamic derangements.
Purpose of the Study:
- To discuss the complex interactions in cardiorenal syndrome.
- To introduce novel serum markers for improved diagnosis of CRS.
- To review current therapeutic strategies for CRS.
Main Methods:
- Literature review of cardiorenal syndrome pathophysiology and treatment.
- Discussion of emerging diagnostic serum markers.
- Analysis of established therapeutic interventions.
Main Results:
- Novel serum markers show promise for enhancing CRS diagnosis compared to traditional creatinine measurements.
- Loop diuretics are the mainstay for acute CRS management.
- ACE-inhibition is crucial for chronic CRS, often continued despite creatinine increases.
Conclusions:
- CRS is a significant clinical challenge requiring improved diagnostic tools.
- Current therapies focus on diuretics and ACE inhibitors.
- Further research into diagnostic markers and treatment optimization is warranted.
Abstract:
Cardiorenal syndrome (CRS) describes the reciprocally detrimental interaction between both acute and chronic cardiac and renal dysfunction. The syndrome is prevalent and carries a high mortality. CRS has five clinical subtypes, which share common pathogenetic mechanisms including neurohumoral and haemodynamic derangements. We describe several serum markers that offer improvements over traditional measurement of serum creatinine for the diagnosis of CRS. The mainstay of therapy of CRS is loop diuretics in the acute setting and ACE-inhibition in the chronic setting, the latter should in most cases continue despite therapy-associated increases in creatinine. Extracorporeal therapies remain second line treatment.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiac Catheterization I: Pre-Procedure Overview
Cardiomyopathy V: Interprofessional Care
Heart Failure II: Pathophysiology

